RMRita S. Mehta

Rita S. Mehta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rita S. Mehta has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Somatic BRCA2 Mutation-Positive Concurrent Accessory Male Breast Cancer (BC) and Non-Small Cell Lung Cancer (NSCLC): Excellent Efficacy of Palbociclib, Fulvestrant and Leuprolide in Platinum-Exposed and Endocrine-Refractory BC Associated with Cyclin D1 and FGFR1 Amplification and of Carboplatin, Paclitaxel and Radiation in NSCLC

    by Yu Cheng, Ningjing Li, Ann Eapen, Ritesh Parajuli, Rita Mehta

    Accessory male breast cancer (BC) is a rare entity and is associated with poor outcome. We report a 76-year-old patient who was diagnosed with concurrent accessory breast and primary lung cancer, both were positive for somatic BRCA-2 (E1593D) mutation. He received concurrent radiation and platinum-based chemotherapy for lung cancer with good response, but breast cancer progressed in about 8 months, and further progressed after single agent anastrozole in 10 months. Next Generation Sequencing (NGS) of breast cancer was also positive for CCND1 (Cyclin D1) and FGFR1 amplifications. Despite a poor molecular profile of breast cancer, and progression following platinum-based chemotherapy and anastrozole, he was successfully treated with the Cyclin-dependent kinase (CKD) 4/6 inhibitor palbociclib, estrogen-receptor down-regulator fulvestrant and luteinizing hormone-releasing hormone (LHRH) agonist leuprolide with the duration of response of 21 months which has exceeded duration of response to prior treatments. This case is of interest given FDA expanded the approval of palbociclib in combination with AI or fulvestrant for male patients with HR–positive, HER2-negative metastatic breast cancer in Apr. 2019 based on real-world data from electronic health records.


  • Open Access

    Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging

    by Bruce J. Tromberg, Zheng Zhang, Anaïs Leproux, Thomas D. O'SUllivan, Albert E. Cerussi, Philip M. Carpenter, Rita S. Mehta, Darren Roblyer, Wei Yang, Keith D. Paulsen, et al.

    The prospective multicenter ACRIN 6691 trial was designed to evaluate whether changes from baseline to mid-therapy in a diffuse optical spectroscopic imaging (DOSI)–derived imaging endpoint, the tissue optical index (TOI), predict pathologic complete response (pCR) in women undergoing breast cancer neoadjuvant chemotherapy (NAC). DOSI instruments were constructed at the University of California, Irvine (Irvine, CA), and delivered to six institutions where 60 subjects with newly diagnosed breast tumors (at least 2 cm in the longest dimension) were enrolled over a 2-year period. Bedside DOSI images of the tissue concentrations of deoxy-hemoglobin (ctHHb), oxy-hemoglobin (ctHbO2), water (ctH2O), lipid, and TOI (ctHHb × ctH2O/lipid) were acquired on both breasts up to four times during NAC treatment: baseline, 1-week, mid-point, and completion. Of the 34 subjects (mean age 48.4 ± 10.7 years) with complete, evaluable data from both normal and tumor-containing breast, 10 (29%) achieved pCR as determined by central pathology review. The percent change in tumor-to-normal TOI ratio (%TOITN) from baseline to mid-therapy ranged from −82% to 321%, with a median of −36%. Using pCR as the reference standard and ROC curve methodology, %TOITN AUC was 0.60 (95% CI, 0.39–0.81). In the cohort of 17 patients with baseline tumor oxygen saturation (%StO2) greater than the 77% population median, %TOITN AUC improved to 0.83 (95% CI, 0.63–1.00). We conclude that the combination of baseline functional properties and dynamic optical response shows promise for clinical outcome prediction. Cancer Res; 76(20); 5933–44. ©2016 AACR.


  • Top Cited Papers

    Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer

    by Rita S. Mehta, William E. Barlow, Kathy S. Albain, Ted A. Vandenberg, Shaker R. Dakhil, Nagendra R. Tirumali, Danika L. Lew, Daniel F. Hayes, Julie R. Gralow, Robert B. Livingston, et al.

    The aromatase inhibitor anastrozole inhibits estrogen synthesis. Fulvestrant binds and accelerates degradation of estrogen receptors. We hypothesized that these two agents in combination might be more effective than anastrozole alone in patients with hormone-receptor (HR)–positive metastatic breast cancer. Postmenopausal women with previously untreated metastatic disease were randomly assigned, in a 1:1 ratio, to receive either 1 mg of anastrozole orally every day (group 1), with crossover to fulvestrant alone strongly encouraged if the disease progressed, or anastrozole and fulvestrant in combination (group 2). Patients were stratified according to prior or no prior receipt of adjuvant tamoxifen therapy. Fulvestrant was administered intramuscularly at a dose of 500 mg on day 1 and 250 mg on days 14 and 28 and monthly thereafter. The primary end point was progression-free survival, with overall survival designated as a prespecified secondary outcome. The median progression-free survival was 13.5 months in group 1 and 15.0 months in group 2 (hazard ratio for progression or death with combination therapy, 0.80; 95% confidence interval [CI], 0.68 to 0.94; P=0.007 by the log-rank test). The combination therapy was generally more effective than anastrozole alone in all subgroups, with no significant interactions. Overall survival was also longer with combination therapy (median, 41.3 months in group 1 and 47.7 months in group 2; hazard ratio for death, 0.81; 95% CI, 0.65 to 1.00; P=0.05 by the log-rank test), despite the fact that 41% of the patients in group 1 crossed over to fulvestrant after progression. Three deaths that were possibly associated with treatment occurred in group 2. The rates of grade 3 to 5 toxic effects did not differ significantly between the two groups. The combination of anastrozole and fulvestrant was superior to anastrozole alone or sequential anastrozole and fulvestrant for the treatment of HR-positive metastatic breast cancer, despite the use of a dose of fulvestrant that was below the current standard. (Funded by the National Cancer Institute and AstraZeneca; SWOG ClinicalTrials.gov number, NCT00075764.)


  • Open Access

    NON-INVASIVE MEASUREMENT OF DEEP TISSUE TEMPERATURE CHANGES CAUSED BY APOPTOSIS DURING BREAST CANCER NEOADJUVANT CHEMOTHERAPY: A CASE STUDY

    by So Hyun Chung, Rita Mehta, Bruce J. Tromberg, A. G. Yodh

    Treatment-induced apoptosis of cancer cells is one goal of cancer therapy. Interestingly, more heat is generated by mitochondria during apoptosis, especially the uncoupled apoptotic state,1,2compared to the resting state. In this case study, we explore these thermal effects by longitudinally measuring temperature variations in a breast lesion of a pathological complete responder during neoadjuvant chemotherapy (NAC). Diffuse Optical Spectroscopic Imaging (DOSI) was employed to derive absolute deep tissue temperature using subtle spectral features of the water peak at 975 nm.3A significant temperature increase was observed in time windows during the anthracycline and cyclophosphamide (AC) regimen but not in the paclitaxel and bevacizumab regimen. Hemoglobin concentration changes generally did not follow temperature, suggesting the measured temperature increases were likely due to mitochondrial uncoupling rather than a direct vascular effect. A simultaneous increase of tissue oxygen saturation with temperature was observed, suggesting that oxidative stress also contributes to apoptosis. Although preliminary, this study indicates longitudinal DOSI tissue temperature monitoring provides information that can improve our understanding of the mechanisms of tissue response during NAC.


  • Open Access

    Oligohydramnios associated with administration of weekly paclitaxel for triple-negative breast cancer during pregnancy

    by M. P. Shieh, R. S. Mehta

    A 35-year-old multipara presented at 17 weeks gestation with a right breast mass and bloody nipple discharge. On examination, she had a palpable 10 × 9 cm right breast mass and a 4 cm right axillary lymph node. A core biopsy revealed invasive ductal carcinoma. The tumor was negative for estrogen, progesterone, and HER2 receptors—a triple-negative phenotype. Limited staging with liver ultrasound and magnetic resonance imaging of T- and L-spine were unrevealing for metastases.


  • Open Access

    Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry

    by Jason A Zell, Walter Y Tsang, Thomas H Taylor, Rita S Mehta, Hoda Anton-Culver

    Introduction: Inflammatory breast cancer (IBC) is an aggressive form of breast cancer associated with overexpression of Her2/Neu (human epidermal growth factor-like receptor 2 (HER2)) and poor survival. We investigated survival differences for IBC patient cases based on hormone receptor status and HER2 receptor status using data from the California Cancer Registry, as contrasted with locally advanced breast cancer (LABC), metastatic breast cancer (MBC) and non-T4 breast cancer. Methods: A case-only analysis of 80,099 incident female breast cancer patient cases in the California Cancer Registry during 1999 to 2003 was performed, with follow-up through March 2007. Overall survival (OS) and breast cancer-specific survival (BC-SS) were analyzed using Kaplan–Meier methods and Cox proportional hazards ratios. Results: A total of 2,014 IBC, 1,268 LABC, 3,059 MBC, and 73,758 non-T4 breast cancer patient cases were identified. HER2+ was associated with advanced tumor stage (P < 0.0001). IBC patient cases were more likely to be HER2+ (40%) and less likely to be hormone receptor-positive (HmR+) (59%) compared with LABC (35% and 69%, respectively), MBC (35% and 74%), and non-T4 patient cases (22% and 82%). HmR+ status was associated with improved OS and BC-SS for each breast cancer subtype after adjustment for clinically relevant factors. In multivariate analysis, HER2+ (versus HER2-) status was associated with poor BC-SS for non-T4 patient cases (hazards ratio = 1.16, 95% confidence interval 1.05 to 1.28) and had a borderline significant association with improved BC-SS for IBC (hazards ratio = 0.82, 95% confidence interval = 0.68 to 0.99). Conclusions: Despite an association with advanced tumor stage, HER2+ status is not an independent adverse prognostic factor for survival among IBC patient cases.


  • Trastuzumab in inflammatory breast cancer

    by R. S. Mehta, T. Schubbert, K. Kong

    Inflammatory breast cancer (IBC) is associated with poor survival, specifically hormone receptor-negative subtype [1].


    • 1 August 2006
      • Vol. 5  (4) , 401-10

    Comparison of choline and pharmacokinetic parameters in breast cancer measured by MR spectroscopic imaging and dynamic contrast enhanced MRI.

    by Min-Ying Su, Hyun-Man Baik, Hon J Yu, Jeon-Hor Chen, Rita S Mehta, Orhan Nalcioglu

    Although an MRI scanner is a single stand-alone modality, different acquisition techniques may be applied to collect structural and functional information, including vascular or angiogenic properties measured by dynamic contrast enhanced MRI (DCE-MRI) and Choline (Cho) metabolism measured by proton MR spectroscopy imaging (MRSI). They may provide complementary information for a better characterization of neoplasm. In this study, we investigated the correlation between Choline measured by MRSI and vascular parameters measured by DCE-MRI in breast cancer. Fourteen patients with histologically proven invasive breast cancer were included. MRSI from a grid of 8 x 8 voxels within a selected slab from each lesion was performed. Each voxel was 1.0 x 1.0 x 1.2 cm3. Choline signal-to-noise ratio (SNR) was measured from each voxel showing an identifiable Choline peak. Corresponding DCE kinetics was measured from each voxel, and analyzed with a 2-compartmental model to obtain pharmacokinetic parameters Ktrans and k(ep). All parameters showed a wide variation within each lesion, and there were no consistent correlations between regional Cho and DCE parameters within the lesion of each individual patient. This finding might be attributed to the heterogeneous nature of breast cancer. The characteristic Cho and DCE-MRI parameters were obtained for each patient by averaging over all Cho-positive voxels. In these 14 patients there was a significant linear correlation between Cho with percent enhancement at 2 min after injection, SE%-2min (r = 0.75, p = 0.002), and pharmacokinetic parameters Ktrans (r = 0.74, p = 0.003), and k(ep) (r = 0.76, p = 0.002). The results suggested that overall there is a correlation between Choline metabolism and angiogenesis activity. Since Choline is associated with cell replication and angiogenesis is required to support tumor growth, this might explain the correlation between these two sets of measures among different lesions.